Related Experiment Video

Updated: May 24, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Targeting MEF2A suppresses microglial hyperactivation and synaptic phagocytosis to attenuate epilepsy pathogenesis

Jingheng Wu1,2, Jiayuanyuan Fu1,2, Shuai Wang3

  • 1Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin Medical University, Tianjin, China.

Cell Death & Disease
|May 22, 2026
PubMed

Insights

Researchers uncovered a signaling pathway where neuronal damage triggers microglial overactivation in epilepsy. Targeting this pathway with MEF2A inhibitors reduced seizure severity and cognitive issues, offering new therapeutic strategies for epilepsy.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • The role of microglia in epilepsy via neuroimmune communication is not well understood.
  • Mechanisms linking neuronal activation of microglia and microglial effects on neuronal activity driving seizure-related inflammation are unclear.

Purpose of the Study:

  • To elucidate the signaling axis connecting pathological adenosine triphosphate (ATP) release during epileptiform activity to microglial MEF2A-dependent hyperactivation.
  • To investigate how this axis exacerbates epilepsy pathology and identify potential therapeutic targets.

Main Methods:

  • Utilized epilepsy models to study the effects of seizures on neuronal activity and microglial responses.
  • Investigated the role of ATP, P2X7 receptors, Ca2+, MEF2A, CD74, NEK7, and NLRP3 inflammasome in microglial hyperactivation.
  • Employed parecoxib and AAV-mediated knockdown to target microglial MEF2A.

Main Results:

  • Seizures induce excessive ATP release, activating microglial P2X7 receptors and leading to CAMKII phosphorylation.
  • This triggers MEF2A acetylation, enhancing CD74 and NEK7 expression, which promotes NLRP3 inflammasome activation and microglial hyperactivation.
  • Targeting microglial MEF2A reduced seizure severity, cognitive deficits, and restored synaptic inhibition by decreasing microglial phagocytosis.

Conclusions:

  • An ATP-P2X7-Ca2+-MEF2A signaling axis connects neuronal injury to pathogenic microglial activation in epilepsy.
  • MEF2A represents a promising therapeutic target for restoring microglial-neuronal homeostasis and treating epilepsy.

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...